← Human Trials & Peer-Reviewed Studies
Mediators of the effect of nicotine pre-treatment on quitting smoking.
Plain-language guide to PMID 30066385 (2018): randomized controlled trial of Therapeutic nicotine (patch, non-peptide).
Key Facts
- PMID
- 30066385
- Journal
- Addiction (Abingdon, England)
- Year
- 2018
- Study type
- Randomized Controlled Trial
- Authors
- Hajek P et al. (6 authors)
- DOI
- 10.1111/add.14401
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Therapeutic nicotine (patch, non-peptide).
Using smoking cessation medications for several weeks prior to quitting smoking facilitates quitting success, but how it does so is not clear.
The researchers investigated these pathways using data from a large trial of nicotine pre-loading, using mediation analysis.
Who Took Part
The age groups tagged for this paper are adults and middle-aged adults, both men and women.
A total of 1792 smokers who wanted to quit attending specialist smoking cessation services in England were enrolled between 13 August 2012 and 10 March 2015.
How the Study Was Run
The researchers set it up as a randomized study.
Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.
Randomized controlled trial of nicotine pre-loading.
Potential mediators were assessed at baseline and 1 week into the pre-loading (3 weeks prior to quitting).
In addition to this, urges to smoke in abstainers were assessed 1 week after the target quit date.
The primary outcome, selected for its proximity in time to potential mediators, was biochemically validated abstinence from smoking at 4 weeks post-target quit date.
What Was Measured
PubMed files the paper under topics including Behavior Therapy, Bupropion, Nicotine, Premedication, Smoking, Smoking Cessation and Smoking Cessation Agents.
Author keywords: Mediators, nicotine replacement, pre-loading and tobacco.
What This Means in Plain Language
The paper is a randomized study of Therapeutic nicotine (patch, non-peptide).
The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2018 (Addiction (Abingdon, England)), a journal based in England.
More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.
Our Notes on the Compound
Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.